<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>91-BETA-2-MIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG1>
<DRUG2>
<DRUG name="HALOTHANE" rxcui="5095">
<ATC code="N01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Interrupt treatment with the beta-2 agonist if the anesthesia must be done with halothane</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>91-BETA-2-MIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG1>
<DRUG2>
<DRUG name="INSULIN" rxcui="5856">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Elevation of the glycemia by the beta-2 mimetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce blood and urine monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>91-BETA-2-MIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>Elevation of the glycemia by the beta-2 mimetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce blood and urine monitoring. Possibly change to insulin, if the situation requires. </COMMENT>
</INTERACTION>
</INTERACTIONS>
